Palvella Therapeutics Inc
palvellatx.comWhat Do They Do?
Develops topical drug candidates for patients with rare skin diseases and vascular malformations, using its QTORIN platform to pursue treatments that act locally in the skin.
10-K for FY2025, filed Mar 31, 2026We are a clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$21.9MView ↗
- ▲ +131% (Loss)
- vs −$9.5M in Q2 FY2025
From protein drugs to skin therapies
Moved from discovering and developing protein medicines across respiratory and cancer programs, with pharmaceutical-company collaborations, to developing topical treatments for rare skin diseases and vascular malformations.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026We are a clinical-stage biopharmaceutical company whose vision is to become the leading rare disease biopharmaceutical company focused on…View ↗
Who Do They Compete With?
Competes with Kaken Pharmaceutical, Nobelpharma, Novartis Pharmaceuticals, Protara Therapeutics, Relay Therapeutics, Vaderis Therapeutics, and Quoin Pharmaceuticals
10-K for FY2025, filed Mar 31, 2026The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong…View ↗
Loading...
